The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

Stefan Flasche; Albert Jan Van Hoek; David Goldblatt; W. John Edmunds; Katherine L. O’Brien; J. Anthony G. Scott; Elizabeth Miller

doi:10.1371/journal.pmed.1001839

The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

Stefan Flasche^*, Albert Jan Van Hoek, David Goldblatt, W. John Edmunds, Katherine L. O’Brien, J. Anthony G. Scott, Elizabeth Miller

^*Corresponding author for this work

Pillar Testing Staff budget centre

Research output: Contribution to journal › Article › peer-review

52 Citations (Scopus)

Original language	English
Article number	e1001839
Journal	PLoS Medicine
Volume	12
Issue number	6
DOIs	https://doi.org/10.1371/journal.pmed.1001839
Publication status	Published - 1 Jun 2015

Bibliographical note

Funding Information:
I have read the journal's policy and have the following conflicts: KLOB has research funding related to pneumococcal vaccine from National Institutes of Health, Glaxosmithkline, Pfizer, the Bill & Melinda Gates Foundation, and Gavi, The Vaccine Alliance. DG’s laboratory is in receipt of collaborative and/or contract funding from vaccine manufacturers including Merck, Sanofi Pasteur, GSK, and Novartis, and DG has received honoraria or consulting fees in the past from Merck, GSK, Sanofi Pasteur, Novartis, and Pfizer. WJE’s partner works for GSK. JAGS is a member of the Joint Committee of Vaccination and Immunisation, has received financial support for research on pneumococcal vaccines from the Wellcome Trust, the National Institute for Health Research (UK), GAVI—the Vaccine Alliance, and PATH Vaccine Solutions, has done consultancy work on pneumococcal vaccines for PATH Vaccine Solutions, and received financial support for research by GSK in 2009/10. SF, AJVH and EM declare no conflict of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pmed.1001839

Cite this

@article{36ce8f1b836c40069d5055024234e151,

title = "The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries",

author = "Stefan Flasche and {Van Hoek}, {Albert Jan} and David Goldblatt and Edmunds, {W. John} and O{\textquoteright}Brien, {Katherine L.} and Scott, {J. Anthony G.} and Elizabeth Miller",

note = "Funding Information: I have read the journal's policy and have the following conflicts: KLOB has research funding related to pneumococcal vaccine from National Institutes of Health, Glaxosmithkline, Pfizer, the Bill & Melinda Gates Foundation, and Gavi, The Vaccine Alliance. DG{\textquoteright}s laboratory is in receipt of collaborative and/or contract funding from vaccine manufacturers including Merck, Sanofi Pasteur, GSK, and Novartis, and DG has received honoraria or consulting fees in the past from Merck, GSK, Sanofi Pasteur, Novartis, and Pfizer. WJE{\textquoteright}s partner works for GSK. JAGS is a member of the Joint Committee of Vaccination and Immunisation, has received financial support for research on pneumococcal vaccines from the Wellcome Trust, the National Institute for Health Research (UK), GAVI—the Vaccine Alliance, and PATH Vaccine Solutions, has done consultancy work on pneumococcal vaccines for PATH Vaccine Solutions, and received financial support for research by GSK in 2009/10. SF, AJVH and EM declare no conflict of interest. ",

year = "2015",

month = jun,

day = "1",

doi = "10.1371/journal.pmed.1001839",

language = "English",

volume = "12",

journal = "PLoS Medicine",

issn = "1549-1277",

publisher = "Public Library of Science",

number = "6",

}

TY - JOUR

T1 - The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

AU - Flasche, Stefan

AU - Van Hoek, Albert Jan

AU - Goldblatt, David

AU - Edmunds, W. John

AU - O’Brien, Katherine L.

AU - Scott, J. Anthony G.

AU - Miller, Elizabeth

N1 - Funding Information: I have read the journal's policy and have the following conflicts: KLOB has research funding related to pneumococcal vaccine from National Institutes of Health, Glaxosmithkline, Pfizer, the Bill & Melinda Gates Foundation, and Gavi, The Vaccine Alliance. DG’s laboratory is in receipt of collaborative and/or contract funding from vaccine manufacturers including Merck, Sanofi Pasteur, GSK, and Novartis, and DG has received honoraria or consulting fees in the past from Merck, GSK, Sanofi Pasteur, Novartis, and Pfizer. WJE’s partner works for GSK. JAGS is a member of the Joint Committee of Vaccination and Immunisation, has received financial support for research on pneumococcal vaccines from the Wellcome Trust, the National Institute for Health Research (UK), GAVI—the Vaccine Alliance, and PATH Vaccine Solutions, has done consultancy work on pneumococcal vaccines for PATH Vaccine Solutions, and received financial support for research by GSK in 2009/10. SF, AJVH and EM declare no conflict of interest.

PY - 2015/6/1

Y1 - 2015/6/1

UR - http://www.scopus.com/inward/record.url?scp=84937774717&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.1001839

DO - 10.1371/journal.pmed.1001839

M3 - Article

C2 - 26057994

AN - SCOPUS:84937774717

SN - 1549-1277

VL - 12

JO - PLoS Medicine

JF - PLoS Medicine

IS - 6

M1 - e1001839

ER -

The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this